Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25
04:56pm, Thursday, 21'st Aug 2025
IOVA's Amtagvi (lifileucel) launch shows progress with Q2'25 revenue growth, helping rebuild confidence after prior stagnation. Cash burn remains a concern, but the company announced a restructuring w
Why Iovance Biotherapeutics Stock Was Climbing Today
03:16pm, Tuesday, 19'th Aug 2025
A piece of good news on the regulatory front and a subsequent bullish analyst update were the factors driving Iovance Biotherapeutics (IOVA 5.00%) stock higher on Tuesday. The shares were almost 6% in
Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
04:15pm, Monday, 18'th Aug 2025
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
04:21am, Saturday, 09'th Aug 2025
Experienced investors understand that being in the stock market requires a long-term, multiyear mindset. For truly patient people though, the reward is well worth the wait; you'd be hard-pressed to fi
Why Iovance Biotherapeutics Stock Plummeted Today
07:31pm, Friday, 08'th Aug 2025
Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (IOVA -20.08%
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
01:51pm, Friday, 08'th Aug 2025
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript
03:15am, Friday, 08'th Aug 2025
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel G. Kirby - Chief Commercial Officer Frederick G.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
06:10pm, Thursday, 07'th Aug 2025
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago.
Iovance (IOVA) Q2 Revenue Jumps 93%
04:44pm, Thursday, 07'th Aug 2025
Iovance (IOVA) Q2 Revenue Jumps 93%
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
04:01pm, Thursday, 07'th Aug 2025
$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reit
Is Iovance Biotherapeutics Stock Due for a Big Rally?
04:46am, Wednesday, 30'th Jul 2025
Shares of Iovance Biotherapeutics (IOVA -1.02%) have been in a free fall this past year, but in recent weeks, they have experienced a bit of a surge in value. The volatile biotech stock has been picki
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
03:29am, Tuesday, 29'th Jul 2025
Shares of Iovance Biotherapeutics (IOVA -5.91%) are down about 75% from a high-water mark they set last December. Up and down Wall Street, investment bank analysts tasked with following the commercial
Here's why Iova stock surged 32% today and why the rally might not be over
12:08pm, Wednesday, 23'rd Jul 2025
Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months. The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight ran
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 18'th Jul 2025
SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
12:02pm, Friday, 18'th Jul 2025
Iovance Biotherapeutics, Inc. stock is down nearly 30% since my "sell" recommendation in April. Q1 earnings disappointed, with Amtagvi sales underperforming the Street's expectations and guidance revi
